BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8197951)

  • 1. Life-threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received gadopentetate dimeglumine.
    Witte RJ; Anzai LL
    AJNR Am J Neuroradiol; 1994 Mar; 15(3):523-4. PubMed ID: 8197951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anaphylactoid reaction caused by intravenous gadopentetate dimeglumine in magnetic resonance].
    Campos A; Aznar L; Alamar R; Castelló JV
    Med Clin (Barc); 1996 Feb; 106(5):197. PubMed ID: 8684023
    [No Abstract]   [Full Text] [Related]  

  • 3. Anaphylactoid reactions to i.v. gadopentetate dimeglumine.
    Tishler S; Hoffman JC
    AJNR Am J Neuroradiol; 1990; 11(6):1167; discussion 1168-9. PubMed ID: 2124049
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse reaction to intravenous gadoteridol.
    Shellock FG; Hahn HP; Mink JH; Itskovich E
    Radiology; 1993 Oct; 189(1):151-2. PubMed ID: 8372186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Artificial contrasting during magnetic resonance tomography].
    Sergeev PV; Panov OV; Egorova SV; Bolotova EN; Shimanovskii NL; Akhadov TA; Sviridov NK
    Vestn Rentgenol Radiol; 1997; (1):45-52. PubMed ID: 9133071
    [No Abstract]   [Full Text] [Related]  

  • 6. Dosage of gadoteridol and adverse reactions relative to gadopentetate.
    Hieronim DE; Kanal E; Swanson DP
    Am J Health Syst Pharm; 1995 Nov; 52(22):2556-9. PubMed ID: 8590239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential neurotoxic effects of gadopentetate dimeglumine: clinical significance.
    Alhassan A; Weinmann HJ
    AJNR Am J Neuroradiol; 1997 Apr; 18(4):785-6; author reply 786-8. PubMed ID: 9127052
    [No Abstract]   [Full Text] [Related]  

  • 8. MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients.
    Kuhn MJ; Hammer GM; Swenson LC; Youssef HT; Gleason TJ
    Comput Med Imaging Graph; 1994; 18(5):391-9. PubMed ID: 7954317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical safety of gadopentetate dimeglumine.
    Nelson KL; Gifford LM; Lauber-Huber C; Gross CA; Lasser TA
    Radiology; 1995 Aug; 196(2):439-43. PubMed ID: 7617858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal reaction to gadopentetate dimeglumine.
    Jordan RM; Mintz RD
    AJR Am J Roentgenol; 1995 Mar; 164(3):743-4. PubMed ID: 7863905
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of the safety and efficacy of gadoteridol injection (a low osmolal magnetic resonance contrast agent). Clinical trials report.
    DeSimone D; Morris M; Rhoda C; Lucas T; Zielonka J; Olukotun A; Carvlin M
    Invest Radiol; 1991 Nov; 26 Suppl 1():S212-6; discussion S232-5. PubMed ID: 1808133
    [No Abstract]   [Full Text] [Related]  

  • 12. Anaphylactic shock induced by intravenous gadopentetate dimeglumine.
    Tardy B; Guy C; Barral G; Page Y; Ollagnier M; Bertrand JC
    Lancet; 1992 Feb; 339(8791):494. PubMed ID: 1346846
    [No Abstract]   [Full Text] [Related]  

  • 13. Generalized seizure after i.v. administration of gadopentetate dimeglumine.
    Harbury OL
    AJNR Am J Neuroradiol; 1991; 12(4):666. PubMed ID: 1882740
    [No Abstract]   [Full Text] [Related]  

  • 14. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.
    Yuh WT; Fisher DJ; Engelken JD; Greene GM; Sato Y; Ryals TJ; Crain MR; Ehrhardt JC
    Radiology; 1991 Aug; 180(2):485-91. PubMed ID: 2068317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life-threatening anaphylactoid reaction after iv injection of gadoterate meglumine.
    Meuli RA; Maeder P
    AJR Am J Roentgenol; 1996 Mar; 166(3):729. PubMed ID: 8623674
    [No Abstract]   [Full Text] [Related]  

  • 16. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
    Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eye and testicular pain after administration of gadopentetate dimeglumine.
    Padhani AR; Lopez AJ; Revell PB; MacVicar DA
    AJR Am J Roentgenol; 1995 Aug; 165(2):484-5. PubMed ID: 7618587
    [No Abstract]   [Full Text] [Related]  

  • 18. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats.
    Tweedle MF; Wedeking P; Kumar K
    Invest Radiol; 1995 Jun; 30(6):372-80. PubMed ID: 7490190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadoteridol-induced anaphylaxis - not a class allergy.
    Galera C; Pur Ozygit L; Cavigioli S; Bousquet PJ; Demoly P
    Allergy; 2010 Jan; 65(1):132-4. PubMed ID: 19796195
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
    McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
    Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.